As of 2024-12-14, the EV/EBITDA ratio of Cardiff Oncology Inc (CRDF) is -4.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Cardiff's latest enterprise value is 187.39 mil USD. Cardiff's TTM EBITDA according to its financial statements is -46.06 mil USD. Dividing these 2 quantities gives us the above Cardiff EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 15.9x | 14.8x |
| Forward P/E multiples | 15.0x - 15.5x | 15.2x |
| Fair Price | (13.26) - (13.71) | (13.30) |
| Upside | -438.2% - -449.7% | -439.3% |
| Date | EV/EBITDA |
| 2024-12-12 | -3.35 |
| 2024-12-11 | -3.82 |
| 2024-12-10 | -3.91 |
| 2024-12-09 | -2.43 |
| 2024-12-06 | -2.28 |
| 2024-12-05 | -2.31 |
| 2024-12-04 | -2.39 |
| 2024-12-03 | -2.59 |
| 2024-12-02 | -2.67 |
| 2024-11-29 | -2.61 |
| 2024-11-27 | -2.54 |
| 2024-11-26 | -2.45 |
| 2024-11-25 | -2.44 |
| 2024-11-22 | -2.44 |
| 2024-11-21 | -2.49 |
| 2024-11-20 | -2.53 |
| 2024-11-19 | -2.63 |
| 2024-11-18 | -2.58 |
| 2024-11-15 | -2.58 |
| 2024-11-14 | -2.87 |
| 2024-11-13 | -3.01 |
| 2024-11-12 | -3.20 |
| 2024-11-11 | -3.56 |
| 2024-11-08 | -3.14 |
| 2024-11-07 | -4.26 |
| 2024-11-06 | -3.95 |
| 2024-11-05 | -3.81 |
| 2024-11-04 | -3.87 |
| 2024-11-01 | -3.28 |
| 2024-10-31 | -3.18 |
| 2024-10-30 | -3.18 |
| 2024-10-29 | -3.18 |
| 2024-10-28 | -3.04 |
| 2024-10-25 | -2.86 |
| 2024-10-24 | -2.75 |
| 2024-10-23 | -2.89 |
| 2024-10-22 | -2.84 |
| 2024-10-21 | -2.79 |
| 2024-10-18 | -2.94 |
| 2024-10-17 | -2.81 |
| 2024-10-16 | -2.81 |
| 2024-10-15 | -2.68 |
| 2024-10-14 | -2.64 |
| 2024-10-11 | -2.64 |
| 2024-10-10 | -2.51 |
| 2024-10-09 | -2.51 |
| 2024-10-08 | -2.76 |
| 2024-10-07 | -2.68 |
| 2024-10-04 | -2.60 |
| 2024-10-03 | -2.53 |